Trials / Completed
CompletedNCT02213705
Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Assistance Publique - Hôpitaux de Paris · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The main ailm of this phase I-II study is to evaluate toxicity and efficacy of allogenic mesenchymal stem cell therapy to treat severe systemic sclerosis. In practice this treatment will be given to patients with a rapidly evolutive disease or refractory to cyclophosphamide.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS |
Timeline
- Start date
- 2014-05-06
- Primary completion
- 2020-02-09
- Completion
- 2022-06-16
- First posted
- 2014-08-11
- Last updated
- 2024-05-01
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT02213705. Inclusion in this directory is not an endorsement.